The drugmaker raised its 2021 sales forecast for the shot to $33.5 billion, up from $26 billion.
Pfizer expects an adjusted pretax profit in the high 20 percent range of revenue for the shot, CNBC reported. It expects full-year earnings between $3.95 and $4.05 per share, up from its previous estimate of $3.55 to $3.65 per share.
“The second quarter was remarkable in a number of ways,” Pfizer CEO Albert Bourla said in a statement, according to CNBC. “Most visibly, the speed and efficiency of our efforts with BioNTech to help vaccinate the world against COVID-19 have been unprecedented, with now more than a billion doses of BNT162b2 having been delivered globally.”
Pfizer said it could file for emergency use authorization for a booster dose as early as August, CNBC reported. The drugmaker said it expects full approval for its vaccine by January.
Read the full article here.
